PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire …

Artículos que citan PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire …

Título / Autor	Año
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients RS Herbst, JC Soria, M Kowanetz, GD Fine, O Hamid, MS Gordon, ... Nature 515 (7528), 563	2014
Adoptive cell transfer as personalized immunotherapy for human cancer SA Rosenberg, NP Restifo Science 348 (6230), 62-68	2015
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential P Sharma, JP Allison Cell 161 (2), 205-214	2015
Elements of cancer immunity and the cancer–immune set point DS Chen, I Mellman Nature 541 (7637), 321	2017
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations W Zou, JD Wolchok, L Chen Science translational medicine 8 (328), 328rv4-328rv4	2016
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing M Yadav, S Jhunjhunwala, QT Phung, P Lupardus, J Tanguay, ... Nature 515 (7528), 572	2014
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells BM Carreno, V Magrini, M Becker-Hapak, S Kaabinejadian, J Hundal, ... Science 348 (6236), 803-808	2015
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints S Koyama, EA Akbay, YY Li, GS Herter-Sprie, KA Buczkowski, ... Nature communications 7, 10501	2016
Overcoming T cell exhaustion in infection and cancer KE Pauken, EJ Wherry Trends in immunology 36 (4), 265-276	2015
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients A Gros, MR Parkhurst, E Tran, A Pasetto, PF Robbins, S Ilyas, TD Prickett, ... Nature medicine 22 (4), 433	2016
T-cell transfer therapy targeting mutant KRAS in cancer E Tran, PF Robbins, YC Lu, TD Prickett, JJ Gartner, L Jia, A Pasetto, ... New England Journal of Medicine 375 (23), 2255-2262	2016
Immunogenicity of somatic mutations in human gastrointestinal cancers E Tran, M Ahmadzadeh, YC Lu, A Gros, S Turcotte, PF Robbins, ... Science 350 (6266), 1387-1390	2015
Vaccines for established cancer: overcoming the challenges posed by immune evasion SH van der Burg, R Arens, F Ossendorp, T van Hall, CJM Melief Nature Reviews Cancer 16 (4), 219	2016
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? DS Shin, A Ribas Current opinion in immunology 33, 23-35	2015
Non-genomic and immune evolution of melanoma acquiring MAPKi resistance W Hugo, H Shi, L Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ... Cell 162 (6), 1271-1285	2015
MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade PJR Ebert, J Cheung, Y Yang, E McNamara, R Hong, M Moskalenko, ... Immunity 44 (3), 609-621	2016
Clinical relevance of host immunity in breast cancer: from TILs to the clinic P Savas, R Salgado, C Denkert, C Sotiriou, PK Darcy, MJ Smyth, S Loi Nature reviews Clinical oncology 13 (4), 228	2016
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma AI Daud, K Loo, ML Pauli, R Sanchez-Rodriguez, PM Sandoval, ... The Journal of clinical investigation 126 (9), 3447-3452	2016
TGFβ is a master regulator of radiation therapy-induced antitumor immunity C Vanpouille-Box, JM Diamond, KA Pilones, J Zavadil, JS Babb, ... Cancer research 75 (11), 2232-2242	2015
CD8+ CD103+ tumor–infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients F Djenidi, J Adam, A Goubar, A Durgeau, G Meurice, V de Montpréville, ... The Journal of Immunology 194 (7), 3475-3486	2015

1 - 20

Las fechas y los recuentos de citas son estimados y se determinan de forma automática mediante un programa informático.